ATG3 (Gene)

Organism:

Homo sapiens

Synonyms:APG3, APG3-LIKE, APG3L, ATG3, ENTREZ:64422, HGNC:20962, MIM:609606, NM_001278712, NM_022488, NP_001265641, NP_071933, PC3-96, XM_011513074, XP_011511376, autophagy related 3

Omim:OMIM:609606

Id:ENSG00000144848

Hgnc:HGNC:20962

Entrez:64422

Ensembl:ENSG00000144848

Description:autophagy related 3

This gene encodes a ubiquitin-like-conjugating enzyme and is a component of ubiquitination-like systems involved in autophagy, the process of degradation, turnover and recycling of cytoplasmic constituents in eukaryotic cells. This protein is known to play a role in regulation of autophagy during cell death. A pseudogene of this gene is located on chromosome 20. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2013]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ATG3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ATG3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ATG3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ATG3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ATG3.

Results found

Linked to

	Label	Description
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 11 V 6 SULFORAPHANE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 2 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE57871 GLI1 PSMD13 knockdown HCT 116 Vorinostat 11 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE57871 vorinostat HCT 116 11 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169152 3 V 6 IBRUTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 3 V 2 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 5 V 4 VERTEPORFIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 11 V 6 SULFORAPHANE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE139987 1 V 2 ROSIGLITAZONE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE57871 GLI1 PSMD13 knockdown HCT 116 Vorinostat 11 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE57871 vorinostat HCT 116 11 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE169152 3 V 6 IBRUTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE210655 3 V 2 CISPLATIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE151090 5 V 4 VERTEPORFIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.